These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 8712713

  • 1. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI, Boxall FE, Goddard P, Barnard CF, Murrer BA, Kelland LR.
    Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
    Raynaud FI, Odell DE, Kelland LR.
    Br J Cancer; 1996 Aug; 74(3):380-6. PubMed ID: 8695352
    [Abstract] [Full Text] [Related]

  • 8. Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry.
    Poon GK, Raynaud FI, Mistry P, Odell DE, Kelland LR, Harrap KR, Barnard CF, Murrer BA.
    J Chromatogr A; 1995 Sep 29; 712(1):61-6. PubMed ID: 8556156
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ, Kelland LR.
    Cancer Res; 1994 Dec 01; 54(23):6194-200. PubMed ID: 7954466
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.
    Siddik ZH, Thai G, Yoshida M, Zhang YP, Khokhar AR.
    Anticancer Drug Des; 1994 Dec 01; 9(6):495-509. PubMed ID: 7880375
    [Abstract] [Full Text] [Related]

  • 12. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
    Goddard PM, Orr RM, Valenti MR, Barnard CF, Murrer BA, Kelland LR, Harrap KR.
    Anticancer Res; 1996 Dec 01; 16(1):33-8. PubMed ID: 8615631
    [Abstract] [Full Text] [Related]

  • 13. Rapid biotransformation of satraplatin by human red blood cells in vitro.
    Carr JL, Tingle MD, McKeage MJ.
    Cancer Chemother Pharmacol; 2002 Jul 01; 50(1):9-15. PubMed ID: 12111106
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S, Buclin T, Lejeune F, Bauer J, Leyvraz S, Decosterd LA.
    Anticancer Res; 2003 Jul 01; 23(3C):2757-65. PubMed ID: 12926110
    [Abstract] [Full Text] [Related]

  • 15. Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro.
    Bell DN, Liu JJ, Tingle MD, Rattel B, Meyer TU, McKeage MJ.
    Clin Exp Pharmacol Physiol; 2008 Dec 01; 35(12):1440-6. PubMed ID: 18671714
    [Abstract] [Full Text] [Related]

  • 16. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF, Koberle B, Masters JR, Kelland LR.
    Br J Cancer; 1999 Dec 01; 81(8):1294-303. PubMed ID: 10604725
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of therapeutic doses of isotopically labeled platinum antitumor agents in the mouse and rat.
    Robins AB, Leach MO.
    Cancer Treat Rep; 1983 Mar 01; 67(3):245-52. PubMed ID: 6682013
    [Abstract] [Full Text] [Related]

  • 18. [JM216, an orally active platine derivative].
    Lansiaux A, Bailly C.
    Bull Cancer; 2000 Jul 01; 87(7-8):531-6. PubMed ID: 10969209
    [No Abstract] [Full Text] [Related]

  • 19. Binding properties of an orally active platinum anti-tumor drug JM216 with metallothionein in vivo.
    Xing B, Zhu H, Wang Y, Tang W.
    Biometals; 2000 Sep 01; 13(3):203-8. PubMed ID: 11127891
    [Abstract] [Full Text] [Related]

  • 20. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ, Kelland LR, Harrap KR.
    Br J Cancer; 1993 Aug 01; 68(2):240-50. PubMed ID: 8347478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.